Imricor Medical Systems

The Business

IMR develops and sells MRI-compatible catheters and accessories for cardiac electrophysiology (EP), the medical specialty focused on diagnosing and treating abnormal heart rhythms. Traditional cardiac ablation, where targeted energy destroys the tissue causing irregular heartbeats, relies on X-ray imaging, which exposes patients and clinicians to radiation and provides limited soft-tissue visualisation. IMR's NorthStar platform is the only system globally that allows these procedures to be performed inside an MRI scanner, delivering superior imaging without radiation. The business model combines upfront capital equipment sales ($120,000 per site) with recurring consumable catheters ($3,000 per procedure) and annual service fees.

Recent Performance

Revenue fell 70% from $1.0m in FY24 to $292k in FY25, off a base that itself was negligible. The decline reflected clinical trial sites displacing commercial procedures in Europe, where the company holds CE Mark approval. Despite a 40-site EU pipeline, commercial conversion has been minimal. The company burned $19.5m in cash during FY25. Shares have rallied approximately 60% over the past twelve months on FDA momentum, including clearance of 14 of 15 PMA modules and the company's first U.S. diagnostic sale in July 2026.

Outlook

Everything hinges on U.S. PMA approval, the FDA's most rigorous pathway for high-risk medical devices. A 75% probability of approval by H1 2027 is supportable based on regulatory progress to date, which would unlock the ablation catheter market in the United States. Revenue is projected to climb from $1.8m in FY26 to $6.2m by FY28, driven by cumulative site installations and growing procedure volumes. This trajectory, while representing strong percentage growth off a very low base, does not approach the scale required for profitability in the near term. Operating expenses run $21-23m annually and are largely fixed; the company cannot cut its way to breakeven. Meaningful free cash flow generation requires a bull-case outcome, where 160 or more installed sites and substantially higher procedure volumes per site produce terminal revenue well above $20m.

Key Risks

PMA delay or outright rejection would erase the commercial thesis and reprice the stock toward its net cash base. No MRI-guided cardiac ablation device has previously received FDA approval, so the agency's requirements in the final review phase remain untested. Hospital adoption below expectations would confirm that the EU conversion weakness is structural rather than temporary: MRI suites operate under tight scheduling constraints, and cardiologists must learn materially new workflows to perform ablation inside a scanner. If procedure volumes per site settle at 20-30 annually rather than the 60 modelled in the base case, the revenue ramp slows significantly. Finally, cash burn accelerating beyond the current rate of approximately $5m per quarter would force dilutive equity raises, compressing per-share value even in scenarios where the business eventually reaches scale. In the base case, at least one additional raise is required by FY29.

What to Watch

The thesis-defining event is PMA Module 4 submission in Q3-Q4 2026, which will confirm whether the company remains on track for full FDA approval in H1 2027. U.S. site installation data, reported quarterly from Q4 2026, will provide the first real test of hospital adoption velocity.

• Q3-Q4 2026 PMA Module 4 submission — completion of the final major regulatory milestone before FDA review; 80% probability of on-time filing.
• H1 2027 FDA PMA approval decision — binary catalyst with approximately 75% probability; approval would validate the entire commercial thesis.
• Q4 2026 onwards Quarterly U.S. site installations — the first verifiable data on hospital adoption rate and procedure volumes per site.

Company Description

Imricor Medical Systems is a U.S.-headquartered, ASX-listed medical device company focused exclusively on MRI-guided cardiac electrophysiology. The company operates a single business segment with three revenue streams: consumable catheters used during ablation procedures (60% of FY24 revenue), capital equipment installed in hospital MRI suites (30%), and recurring service contracts (10%). The product portfolio centres on the NorthStar platform, which includes diagnostic and ablation catheters, a recording system for monitoring heart signals inside the MRI, and proprietary accessories. IMR holds CE Mark approval for commercial sales in the European Union and has secured 14 of 15 FDA PMA modules for U.S. market access. The company employs approximately 88 people, with facilities in Minnesota (headquarters and manufacturing) and Germany (European commercial operations).

Where the Growth Is

The entire growth thesis sits in U.S. ablation catheter consumables, which currently contribute zero revenue. PMA approval would unlock access to the world's largest cardiac ablation market, valued at approximately $5-6 billion. The base case models 46 U.S. sites by FY36 performing 60 procedures each at $3,200 per catheter, generating $18.9m in consumable revenue at terminal. This single product line accounts for all projected revenue growth. If procedures per site reach 100 instead of 60, which is plausible given that cardiac catheterisation labs typically run 200-500 cases annually, terminal consumable revenue would approximately double to $35m or more, fundamentally changing the margin profile.

Competitive Position

IMR occupies a market of one. No other company offers MRI-compatible cardiac ablation catheters. The barriers to replication are formidable: 20 years of development, 92 patents extending through 2030-2034, and the regulatory burden of proving device safety inside a powerful magnetic field. The largest EP companies, Abbott, Boston Scientific, Johnson & Johnson, and Medtronic, have shown no public interest in MRI compatibility, preferring to invest in pulsed field ablation (PFA), a newer energy source gaining rapid clinical adoption.

This creates a dual dynamic. The absence of direct competition is a structural advantage, but the indirect threat from PFA is material. If PFA delivers sufficiently good outcomes without imaging improvement, the clinical urgency for MRI-guided procedures diminishes. The competitive advantage is narrow and has a window of roughly 5-7 years before patents begin expiring and the strategic landscape clarifies. IMR must commercialise within that window or risk its moat eroding before it generates meaningful returns.

Management & Capital Discipline

Founder-CEO Steve Wedan has led IMR through two decades of development to the threshold of U.S. commercialisation. The regulatory execution has been exceptional: four FDA 510(k) clearances in 18 months, IDE approval for the pivotal trial, and 14 of 15 PMA modules submitted. That track record earns genuine credibility on the technical and regulatory side. Capital allocation has been straightforward: A$86m raised across two placements in 18 months, deployed entirely into regulatory submissions, clinical trials, and manufacturing capability.

Wedan has never run a commercial medical device operation. The promotional language around the U.S. launch contrasts with EU conversion data showing 40 pipeline sites producing just $292k in revenue, a gap that remains unexplained. The combined Chair/CEO role concentrates decision-making in a founder with no proven commercial track record, which is a governance consideration that becomes more material as the company transitions from development to sales execution.

Financial Position

The balance sheet is the strongest element of the IMR story. The company held approximately US$74m in cash and marketable securities at last report, against minimal liabilities (US$5m in convertible notes and US$1m in lease obligations). Net cash of roughly A$0.24 per share provides a verified floor that is independent of commercial outcomes. At the current burn rate of approximately $20m per year, the cash runway extends roughly four years without additional raises. In the base case, where revenue ramps slowly and operating losses persist, the company will likely need at least one additional equity raise by FY29. The bull case, where PMA approval accelerates revenue, could potentially be funded from existing resources through to cash flow breakeven, though that outcome is not the central expectation.